WK-X-34

inhibitor of P-glycoprotein and BCRP (breast cancer resistance protein); structure in first source

Also Known As:

N-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isochinolin-2-yl)ethyl)phenylcarbamoyl)phenyl)-3,4-dimethoxy-benzamide

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Jekerle, Veronika: 2 articles (11/2006 - 07/2006)
2.	Piquette-Miller, Micheline: 2 articles (11/2006 - 07/2006)
3.	Reilly, Raymond M: 2 articles (11/2006 - 07/2006)
4.	Scollard, Deborah A: 2 articles (11/2006 - 07/2006)
5.	Wiese, Michael: 2 articles (11/2006 - 07/2006)
6.	Wang, Jing-Hung: 1 article (11/2006)
7.	Breitbach, Kerstin: 1 article (07/2006)
8.	Klinkhammer, Werner: 1 article (07/2006)

1.	Ovarian Neoplasms (Ovarian Cancer) 07/15/2006 - "WK-X-34 selectively modulates Pgp and BCRP in vitro and in vivo in multidrug resistant ovarian cancer cells, and thus may have potential utility in the treatment of multidrug resistant tumors." 07/15/2006 - "In vivo 99mTc-Sestamibi imaging of human ovarian cancer xenografts was used to evaluate the in vivo efficacy of WK-X-34 in mice. "
2.	Neoplasms (Cancer) 07/15/2006 - "WK-X-34 selectively modulates Pgp and BCRP in vitro and in vivo in multidrug resistant ovarian cancer cells, and thus may have potential utility in the treatment of multidrug resistant tumors." 11/01/2006 - "We tested the suitability of (99m)Tc-sestamibi to image the inhibition of P-glycoprotein (Pgp)-mediated multidrug resistance in tumor cells and xenografts after antisense treatment and/or inhibition with a novel Pgp modulator WK-X-34. " 07/15/2006 - "In vivo, uptake of 99mTc-Sestamibi was significantly increased in A2780/Adr xenograft tumors, brain and intestine (AUCs(0-4h) 136%, 147% and 138%; p < 0.05) in mice dosed with WK-X-34 (20 mg/kg i.p.). "

1.	Technetium Tc 99m Sestamibi (Cardiolite)
2.	Member 1 Subfamily B ATP Binding Cassette Transporter